Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XR-NTX/BUP-XL in Methamphetamine Use Disorder
NCT06233799Phase 3Active, not recruiting
- Sponsor
- National Institute on Drug Abuse
- Start
- Jul 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of naltrexone and bupropion in methamphetamine use disorder (MUD) (2 arms), sponsored by National Institute on Drug Abuse. Primary endpoint: Number of Participants with at least 75% methamphetamine-negative urine drug screen tests at 12 weeks. Started Jul 2024; status: active, not recruiting.
02
Drugs
naltrexonebupropion
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT06233799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233799.